Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
HER2 Negative Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Breast Cancer (2009
)
HER2 Positive Breast Cancer (403
)
Hormone Receptor Positive Breast Cancer (308
)
Triple Negative Breast Cancer (299
)
Estrogen Receptor Positive Breast Cancer (204
)
Male Breast Cancer (9
)
Hormone Receptor Negative Breast Cancer (3
)
Breast Cancer (2009
)
HER2 Positive Breast Cancer (403
)
Hormone Receptor Positive Breast Cancer (308
)
Triple Negative Breast Cancer (299
)
Estrogen Receptor Positive Breast Cancer (204
)
Male Breast Cancer (9
)
Hormone Receptor Negative Breast Cancer (3
)
›
Associations
(415)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
FDA - 1 day (New A1)
sacituzumab govitecan-hziy
Sensitive
:
A1
FDA - 1d
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
FDA - 1 day
sacituzumab govitecan-hziy
Sensitive
:
A1
FDA - 1 day - (New A1)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
BMC Cancer - 5 days (New C3)
palbociclib
Sensitive
:
A1
BMC Cancer - 5d
palbociclib
Sensitive: A1 - Approval
BMC Cancer - 5 days
palbociclib
Sensitive
:
A1
BMC Cancer - 5 days - (New C3)
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
elacestrant
Sensitive: A1 - Approval
FDA - 1 week (New A1)
elacestrant
Sensitive
:
A1
FDA - 1wk
elacestrant
Sensitive: A1 - Approval
FDA - 1 week
elacestrant
Sensitive
:
A1
FDA - 1 week - (New A1)
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
pembrolizumab
Sensitive
:
A2
NCCN - 1wk
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 1 week
pembrolizumab
Sensitive
:
A2
NCCN - 1 week - (New A2)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks (New C3)
CDK6 inhibitor
Sensitive
:
B
Endokrynol Pol - 2wk
CDK6 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks
CDK6 inhibitor
Sensitive
:
B
Endokrynol Pol - 2 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks (New C3)
CDK4 inhibitor
Sensitive
:
B
Endokrynol Pol - 2wk
CDK4 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks
CDK4 inhibitor
Sensitive
:
B
Endokrynol Pol - 2 weeks - (New C3)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks (New B)
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3wk
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3 weeks - (New B)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
HR negative + BRCA1 mutation
HER2 Negative Breast Cancer
HR negative + BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ixabepilone
Sensitive: A2 - Guideline
ixabepilone
Sensitive
:
A2
ixabepilone
Sensitive: A2 - Guideline
ixabepilone
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
toremifene
Sensitive: A2 - Guideline
toremifene
Sensitive
:
A2
toremifene
Sensitive: A2 - Guideline
toremifene
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
anastrozole
Sensitive
:
A2
anastrozole
Sensitive: A2 - Guideline
anastrozole
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
docetaxel + capecitabine
Sensitive: A2 - Guideline
docetaxel + capecitabine
Sensitive
:
A2
docetaxel + capecitabine
Sensitive: A2 - Guideline
docetaxel + capecitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
HR negative + BRCA2 mutation
HER2 Negative Breast Cancer
HR negative + BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login